Page last updated: 2024-11-12
lucilactaene
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
lucilactaene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9909017 |
| CHEMBL ID | 5072627 |
| MeSH ID | M0411234 |
Synonyms (3)
| Synonym |
|---|
| methyl (2e,3e,5e,7e,9e)-11-[(3as,6s,6ar)-3a-hydroxy-5-oxo-3,4,6,6a-tetrahydro-2h-furo[3,2-b]pyrrol-6-yl]-2-ethylidene-4,10-dimethyl-11-oxoundeca-3,5,7,9-tetraenoate |
| lucilactaene |
| CHEMBL5072627 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1818764 | Antimalarial activity against wild-type Plasmodium falcipuram 3D7 assessed as growth inhibition | 2022 | Journal of natural products, 01-28, Volume: 85, Issue:1 | Dihydrolucilactaene, a Potent Antimalarial Compound from |
| AID1818755 | Cytotoxicity against human HeLa cells assessed as growth inhibition | 2022 | Journal of natural products, 01-28, Volume: 85, Issue:1 | Dihydrolucilactaene, a Potent Antimalarial Compound from |
| AID1818761 | Antifungal activity against Aspergillus fumigatus Af293 assessed as growth inhibition | 2022 | Journal of natural products, 01-28, Volume: 85, Issue:1 | Dihydrolucilactaene, a Potent Antimalarial Compound from |
| AID1818763 | Antifungal activity against Candida albicans JCM1542 assessed as growth inhibition | 2022 | Journal of natural products, 01-28, Volume: 85, Issue:1 | Dihydrolucilactaene, a Potent Antimalarial Compound from |
| AID1818756 | Cytotoxicity against human HL-60 cells assessed as growth inhibition | 2022 | Journal of natural products, 01-28, Volume: 85, Issue:1 | Dihydrolucilactaene, a Potent Antimalarial Compound from |
| AID1818762 | Antifungal activity against Pyricularia oryzae kita-1 assessed as growth inhibition | 2022 | Journal of natural products, 01-28, Volume: 85, Issue:1 | Dihydrolucilactaene, a Potent Antimalarial Compound from |
| AID1818760 | Antibacterial activity against Escherichia coli HO141 assessed as growth inhibition | 2022 | Journal of natural products, 01-28, Volume: 85, Issue:1 | Dihydrolucilactaene, a Potent Antimalarial Compound from |
| AID1818759 | Antibacterial activity against Staphylococcus aureus 209 assessed as growth inhibition | 2022 | Journal of natural products, 01-28, Volume: 85, Issue:1 | Dihydrolucilactaene, a Potent Antimalarial Compound from |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||